key: cord-0842179-15uwzjkk authors: Song, J.; Deng, Y.-K.; Wang, H.; Wang, Z.-C.; Liao, B.; Ma, J.; He, C.; Pan, L.; Liu, Y.; Alobid, I.; Wang, D.-Y.; Zeng, M.; Mullol, J.; Liu, Z. title: Self-reported taste and smell disorders in patients with COVID-19: distinct features in China date: 2020-06-15 journal: nan DOI: 10.1101/2020.06.12.20128298 sha: c3885d168917da53c27913e71ae643df740289c3 doc_id: 842179 cord_uid: 15uwzjkk Objectives: We aimed to explore the frequencies of nasal symptoms in patients with COVID-19, including loss of smell and taste, as well as their presentation as the first symptom of the disease and their association with the severity of COVID-19. Methods: In this retrospective study, 1,206 laboratory-confirmed COVID-19 patients were included and followed-up by telephone call one month after discharged from Tongji Hospital, Wuhan. Demographic data, laboratory values, comorbidities, symptoms, and numerical rating scale scores (0-10) of nasal symptoms were extracted from the hospital medical records, and confirmed or reevaluated by the telephone follow-up. Results: From COVID-19 patients (N = 1,172) completing follow-up, 199 (17%) subjects had severe COVID-19 and 342 (29.2%) reported nasal symptoms. The most common nasal symptom was loss of taste (20.6%, median score = 6), while 11.4% had loss of smell (median score = 5). The incidence of nasal symptom including loss of smell and loss of taste as the first onset symptom was <1% in COVID-19 patients. Loss of smell or taste scores showed no correlation with the scores of other nasal symptoms. Loss of taste scores, but not loss of smell scores, were significantly increased in severe vs. non-severe COVID-19 patients. Interleukin (IL)-6 and lactose dehydrogenase (LDH) serum levels positively correlated with loss of taste scores. About 80% of COVID-19 patients recovered from smell and taste dysfunction in 2 weeks. Conclusion: In the Wuhan COVID-19 cohort, only 1 out of 10 hospital admitted patients had loss of smell while 1 out 5 reported loss of taste which was associated to severity of COVID-19. Most patients recovered smell and taste dysfunctions in 2 weeks. Last December 2019, a cluster of viral pneumonia cases identified as coronavirus disease 2019 45 , was reported in Wuhan, China. Subsequently, severe acute respiratory syndrome 46 coronavirus 2 (SARS-CoV-2) has been identified to be the pathogenic cause of COVID-19 [1] [2] [3] . This newly recognized illness has spread rapidly throughout Wuhan (Hubei province) to allover Demographic and clinical characteristics 128 Totally 1,206 patients were enrolled and 1,172 of them completed questionnaires. The follow-129 up rate was 97.2%. Reasons of the lost cases included: refusal to answer questions for personal 130 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020 . . https://doi.org/10.1101 /2020 reasons (n = 23); unable to provide accurate information (n = 6); phone calls were not answered 131 (n = 5). The demographic and clinical characteristics of 1,172 patients are shown in Table 1 . The 132 median age was 61 years (IQR, , and 577 (49.2%) were men. The ratio of severe cases was 133 17% (199/1172) . 134 Of the 1172 cases, 399 (25.1%) reported with at least one comorbidity, and 17.3% having one 135 or more respiratory comorbidities, including allergic rhinitis (AR, 9.8%), chronic rhinosinusitis 136 (CRS, 6.1%), asthma (2.5%) and chronic obstructive pulmonary disease (COPD, 0.9%). The 137 frequency of patients with at least one nasal symptom was up to 29.2%, including nasal obstruction 138 (8.6%; median score, 3), rhinorrhea (10.3%; median score, 3), nasal itching (4.9%; median score, 139 2), sneezing (11.0%; median score, 2), loss of smell (11.4%; median score, 5), and loss of taste 140 (20.6%; median score, 6). The incidence of symptom reported as the first onset symptom was < 141 1% for each individual nasal symptom, including loss of smell and taste. No difference in 142 frequency of patients with loss of smell or taste disorder was found between severe and non-severe 143 COVID-19 cases (Fig 1, A) . The scores of loss of taste but not smell were significantly higher in 144 the patients with severe vs. non-severe vs. 6 [4] [5] [6] [7] [8] ; P = 0.03) (Fig 1, B) . No 145 difference in frequency or score for the other nasal symptoms was found between severe and non-146 severe disease. The data is shown in Table 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020 . . https://doi.org/10.1101 /2020 Given the possibility that some patients might not well distinguish the taste and smell disorder 154 [21, 22] , we compared the differences among the patients only with one smell or taste disorder, 155 the patients with both smell and taste disorder, and the patients without any of these two symptoms. 156 We found that the patients without loss of smell and taste were significant elder than the patients 157 in the other two groups (62 [48-69] years vs 59 [46-67] years, 57.5 [42.75-66] years, P = 0.03). No other difference of clinical characteristics and laboratory measurements was found among the 159 patients in three groups. The data is shown in Table E1 in the Online Supplement. The recovery of olfactory and taste function 162 We found that 82.1% (110/134) of patients with loss of sense of smell and 95.5% (231/242) 163 of patients with loss of taste recovered in one month after discharge. The symptomatic duration 164 days showed no difference between the patients with loss of smell and taste (8 [6-13.25] vs 7 [5-165 14] days, P = 0.52) (Fig 1, C) . Most of them recovered in 14 days after onset of symptom (Fig 1, 166 D). No difference in recovery frequency of smell function was found between severe (83.3%) and 167 non-severe cases (81.8%) (P = 0.99) ( Table 1 ). As to taste disorder, 95.3% patients with severe 168 COVID-19 and 95.5% patients with non-severe COVID-19 recovered, and no difference showed 169 neither (P = 0.99) ( Table 1 ). The data is also shown in Table 1 . Due to the limited number of 170 patients with unrecovered symptoms, we did not compare the differences between recovered and 171 unrecovered patients with loss of smell or loss of taste. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020 . . https://doi.org/10.1101 /2020 Clinical characteristics of COVID-19 patients with different severity of taste and smell disorder positive correlation to the symptom of loss of smell, we subsequently compared the differences 177 among the COVID-19 patients with different severity of loss of taste ( (Fig 2) . In addition, serum levels of interleukin-185 6 (IL-6) and lactate dehydrogenase (LDH) were significantly increased in patients with severe 186 compared to mild and moderate loss of taste group ( Table 2) . Levels of IL-8 were significantly 187 increased in severe and moderate compared to mild loss of taste group (Table 2) . The 188 characteristics of the patients with different severity of taste disorder are shown in Table 2 . In 189 addition, IL-6 and LDH showed mild positive correlations to the symptom scores of loss of taste 190 (ρ = 0.15, P = 0.03; ρ = 0.21, P < 0.01, respectively; Fig 3) . As to the comparison among different severity of loss of smell, we divided the 134 patients 192 with loss of sense of smell into mild (score, 1-3, 23.9%), moderate (score, 4-7; 35.8%) and severe 193 (score, 8-10; 40.3%) group. No prominent difference in clinical and laboratory measurements was 194 found among the patients with different severity (Table 3 and Fig 2) . 195 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10.1101/2020.06.12.20128298 doi: medRxiv preprint To the best of our knowledge, this is the first study on detailed information of manifestations underestimated in previous studies based on medical record analysis [7, 23] . In order to overcome 206 this limitation in real-world setting, we did recalled questionnaires by phone call to reevaluate the 207 presence of airway comorbidities, and frequency and severity of nasal symptoms. As a result, the 208 frequencies of COVID-19 patients with AR and CRS were 9.8% and 6.1%, respectively. Previous 209 studies have reported that adult AR and CRS in general population in China were 17.6% and 8%, 210 respectively, these being higher than the reported for 25] . Recent studies indicate 211 that the increasing eosinophils may be an indicator of 27] . Hence, 212 we cannot rule out the possibility that the comorbidities of allergic and eosinophilic diseases such 213 as AR might be potential protective factors for severe Here, we found that upper respiratory tract symptoms were identified in 29.2% patients with 215 COVID-19, with nasal obstruction, rhinorrhea, nasal itching and sneezing presenting in 216 mild/moderate severity and loss of smell and taste presenting in moderate/severe severity. All of 217 these upper respiratory tract symptoms have been commonly reported in other respiratory viral 218 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020 . . https://doi.org/10.1101 /2020 infection, such as influenza and rhinovirus [28] [29] [30] . Our data suggest that similar with the common 219 respiratory virtues, SARS-CoV-2 may be able to infect upper respiratory tract mucosa and cause 220 similar symptoms [22, 29, 31] . In addition, the result in our Wuhan cohort revealed that the self- Interestingly, the loss of taste and smell were the most common upper respiratory tract 229 symptoms observed in COVID-19 patients in Wuhan, with 17.5% patients having only smell or 230 taste disorder and 7.3% patients having both symptoms. By integrating medical record analysis 231 and follow-up confirmation and reevaluation after discharge, we reported higher rates of smell and 232 taste disorder in the hospitalized patients than an early report from Wuhan, which relied on medical 233 record analysis only and had a smaller sample size [17] . However, the rates of smell and taste 234 disorder in our cohort were much lower than those reported in Europe and America [13] [14] [15] [16] 33] . It 235 may be related to the different characteristics of COVID-19 patients. In our study, asymptomatic 236 patients and non-hospitalized patients with mild symptoms were not included. It is also likely that 237 people with distinct ethnic/culture background may have different response to SARS-CoV-2 238 infection. Previously, no large-sample-size investigation of olfactory and taste disorder in the 239 disease caused by either SARS-CoV-1 or middle east respiratory syndrome coronavirus, that 240 belongs to the same family of coronaviruses, was undertaken. A case report revealed the olfactory 241 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. The present study revealed that 95.5% patients with loss of taste and 82.1% patients with loss 262 of smell recovered spontaneously, and most of them in 2-week time, although the severe 263 impairment of olfactory and smell function may lead to delayed recovery. The spontaneous 264 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10.1101/2020.06.12.20128298 doi: medRxiv preprint recovery may be a result of regeneration of the damaged olfactory epithelium and taste buds [44] . 265 Previously, oral and topical corticosteroids have been proposed to treat viral-associated olfactory 266 loss. However, systemic corticosteroids may impair the viral clearance. Given to the high rate of 267 spontaneous recovery of olfactory and taste function, it seems that there is no need to use 268 corticosteroids for treating olfactory and smell disorder in patients with COVID-19, although their 269 administration can be continued to treat comorbidities such as AR and CRS [45] . 270 We have to acknowledge that there are several limitations of this study. First, the self-reported (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10. 1101 /2020 To the best of our knowledge, this is the largest retrospective cohort study focusing on the 287 symptoms of upper respiratory tract in patients with COVID-19 in China. We found that nearly (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020 . . https://doi.org/10.1101 /2020 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10.1101/2020.06.12.20128298 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020 . . https://doi.org/10.1101 /2020 140 Kruskal-Wallis, χ2 test or Fisher's exact test. "*", vs mild, P < 0.05, "**", vs mild, P < 0.01, " #" , vs 451 moderate, P < 0.05. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10.1101/2020.06.12.20128298 doi: medRxiv preprint numerical rating scale of 0-10, with 0 being "no complaint whatsoever" and 10 being "the worst 487 imaginable complaint. ** P < 0.01 compared to mild loss of taste. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10.1101/2020.06.12.20128298 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10.1101/2020.06.12.20128298 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10.1101/2020.06.12.20128298 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 15, 2020. . https://doi.org/10. 1101 /2020 A pneumonia outbreak Alanine aminotransferase, U/L 18 Urine acid COPD, chronic 460 obstructive pulmonary disease; ERS, erythrocyte sedimentation rate; CRP, C-reactive protein; Ig, 461 immunoglobulin; C, complement. Data is presented as medians and interquartile ranges (IQR) for 462 continuous variables and numbers with percentage for categorical variables χ2 test or Fisher's exact test